Clear surgical margins as a prognostic indicator for disease recurrence, with no impact on survival rates in patients with myxofibrosarcoma
Language English Country England, Great Britain Media electronic
Document type Journal Article
PubMed
38806595
PubMed Central
PMC11133331
DOI
10.1038/s41598-024-63035-6
PII: 10.1038/s41598-024-63035-6
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Fibrosarcoma * surgery pathology mortality MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local * pathology MeSH
- Survival Rate MeSH
- Disease-Free Survival MeSH
- Prognosis MeSH
- Margins of Excision * MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Myxofibrosarcoma presents an infiltrating growth pattern that results in a high tendency for local recurrence. Clear margin resection is challenging because of microscopic infiltration. The purpose of the present study was to analyze the overall and disease-free survival rates of patients with myxofibrosarcoma and the prognostic factors that determine both survival and disease recurrence. Among the 111 patients included in our study, the 5-year overall survival rate was 65.5%. An age of more than 65 years (hazard ratio [HR] 1.9 [95% confidence interval (CI) 1.4-5.6]; p < 0.001), a tumor size of more than 5 cm (HR 2.8 [95% CI 0.9-8.1]; p = 0.049) and the G3 tumor grade (HR 14.1 [95% CI 2.1-105.0]; p < 0.001) negatively affected overall survival. The 5-year recurrence-free survival rate was 49.4%. R1/R2-type resection (HR 2.4 [95% CI 1.0-5.6]; p = 0.048) had a detrimental effect on tumor recurrence. Clear margins had a positive impact on recurrence-free survival, but did not significantly affect overall patient survival, suggesting that other factors may play a more significant role in determining patient outcomes. A surgical margin of 2 mm was not sufficient to significantly influence the incidence of recurrence. Consequently, a wider surgical margin may be necessary to reduce the risk of myxofibrosarcoma recurrence.
1st Department of Orthopaedic Surgery St Anne's University Hospital 60200 Brno Czech Republic
1st Pathology Department St Anne's University Hospital 60200 Brno Czech Republic
Clinic of Comprehensive Cancer Care Masaryk Memorial Cancer Institute 60200 Brno Czech Republic
Department of Radiation Oncology Masaryk Memorial Cancer Institute 60200 Brno Czech Republic
Faculty of Medicine Masaryk University 62500 Brno Czech Republic
See more in PubMed
Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977;39:1672–1685. doi: 10.1002/1097-0142(197704)39:4<1672::AID-CNCR2820390442>3.0.CO;2-C. PubMed DOI
Angervall L, Kindblom LG, Merck C. Myxofibrosarcoma. A study of 30 cases. Acta Pathol. Microbiol. Scand. A. 1977;85A:127–140. PubMed
Meis-Kindblom JM, Kindblom LG. Acral myxoinflammatory fibroblastic sarcoma: A low-grade tumor of the hands and feet. Am. J. Surg. Pathol. 1998;22:911–924. doi: 10.1097/00000478-199808000-00001. PubMed DOI
WHO . Classification of Tumours of Soft Tissue and Bone. IARC Press; 2013.
Vanni S, et al. Myxofibrosarcoma landscape: Diagnostic pitfalls, clinical management and future perspectives. Ther. Adv. Med. Oncol. 2022;14:175883592210939. doi: 10.1177/17588359221093973. PubMed DOI PMC
Widemann BC, Italiano A. Biology and management of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and malignant peripheral nerve sheath tumors: State of the art and perspectives. JCO. 2018;36:160–167. doi: 10.1200/JCO.2017.75.3467. PubMed DOI PMC
Sambri A, et al. Does pre-operative MRI predict the risk of local recurrence in primary myxofibrosarcoma of the extremities? Asia-Pac. J. Clin. Oncol. 2019 doi: 10.1111/ajco.13161. PubMed DOI
Lohberger B, et al. Establishment of a novel cellular model for myxofibrosarcoma heterogeneity. Sci. Rep. 2017;7:44700. doi: 10.1038/srep44700. PubMed DOI PMC
Look Hong NJ, et al. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann. Surg. Oncol. 2013;20:80–86. doi: 10.1245/s10434-012-2572-3. PubMed DOI PMC
Odei B, et al. Predictors of local recurrence in patients with myxofibrosarcoma. Am. J. Clin. Oncol. 2018;41:827–831. doi: 10.1097/COC.0000000000000382. PubMed DOI
Song B, Lee K, Lee C, Moon KC. Prognostic significance of microscopic tumor extension in local recurrence of myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Pathol. Int. 2018;68:509–516. doi: 10.1111/pin.12709. PubMed DOI
Sanfilippo R, et al. Myxofibrosarcoma: Prognostic factors and survival in a series of patients treated at a single institution. Ann. Surg. Oncol. 2011;18:720–725. doi: 10.1245/s10434-010-1341-4. PubMed DOI
Gronchi A, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: Local control directly impacts survival. Ann. Surg. 2010;251:506–511. doi: 10.1097/SLA.0b013e3181cf87fa. PubMed DOI
Fujiwara T, et al. The role of surgical margin quality in myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Eur. J. Surg. Oncol. 2021;47:1756–1762. doi: 10.1016/j.ejso.2020.11.144. PubMed DOI
van der Horst CAJ, et al. Overall survival of patients with myxofibrosarcomas: An epidemiological study. Cancers. 2022;14:1102. doi: 10.3390/cancers14051102. PubMed DOI PMC
Morita T, et al. Clinical relevance and functional significance of cell-free microRNA-1260b expression profiles in infiltrative myxofibrosarcoma. Sci. Rep. 2020;10:9414. doi: 10.1038/s41598-020-66120-8. PubMed DOI PMC
Mühlhofer HML, et al. Prognostic factors and outcomes for patients with myxofibrosarcoma: A 13-year retrospective evaluation. Anticancer Res. 2019;39:2985–2992. doi: 10.21873/anticanres.13430. PubMed DOI
Dewan V, Darbyshire A, Sumathi V, Jeys L, Grimer R. Prognostic and survival factors in myxofibrosarcomas. Sarcoma. 2012;2012:1–5. doi: 10.1155/2012/830879. PubMed DOI PMC
Sambri A, Bianchi G, Righi A, Ferrari C, Donati D. Surgical margins do not affect prognosis in high grade myxofibrosarcoma. Eur. J. Surg. Oncol. (EJSO) 2016;42:1042–1048. doi: 10.1016/j.ejso.2016.05.015. PubMed DOI
Melis AS, et al. Incidence of unplanned excisions of soft tissue sarcomas in the Netherlands: A population-based study. Eur. J. Surg. Oncol. 2022;48:994–1000. doi: 10.1016/j.ejso.2021.11.123. PubMed DOI
Pretell-Mazzini J, Barton MD, Conway SA, Temple HT. Unplanned excision of soft-tissue sarcomas: current concepts for management and prognosis. J. Bone Jt. Surg. 2015;97:597–603. doi: 10.2106/JBJS.N.00649. PubMed DOI
Liang Y, et al. The impact of unplanned excision on the outcomes of patients with soft tissue sarcoma of the trunk and extremity: A propensity score matching analysis. Front. Oncol. 2021;10:617590. doi: 10.3389/fonc.2020.617590. PubMed DOI PMC
Kikuta K, et al. An analysis of factors related to recurrence of myxofibrosarcoma. Jpn. J. Clin. Oncol. 2013;43:1093–1104. doi: 10.1093/jjco/hyt119. PubMed DOI
Teurneau H, Engellau J, Ghanei I, Vult von Steyern F, Styring E. High recurrence rate of myxofibrosarcoma: The effect of radiotherapy is not clear. Sarcoma. 2019;2019:1–8. doi: 10.1155/2019/8517371. PubMed DOI PMC
Lee AY, et al. Optimal percent myxoid component to predict outcome in high-grade myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Ann. Surg. Oncol. 2016;23:818–825. doi: 10.1245/s10434-015-5063-5. PubMed DOI PMC
Boughzala-Bennadji R, et al. Localized myxofibrosarcomas: Roles of surgical margins and adjuvant radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2018;102:399–406. doi: 10.1016/j.ijrobp.2018.05.055. PubMed DOI
